The end result of a Phase IIa might well be (is likely to be IMHO) an early approval. In which case, NNVC would have no need of a partnership unless by "partner" what you mean is a "distributor",
But I hope you're right. I'd rather see NNVC go it alone. If FluCide lives up to its potential it should be one of the easiest drugs to market ever.